Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8880908 | 0.91 | ALDH1A1 (0.38) | HSD11B1MAPTSLC29A1TDP1PAOX | |
| SCHEMBL3318840 | 0.86 | HSD11B1 (0.45) | HSD11B1SLC29A1TDP1GBA1DRD2 | |
| SCHEMBL6043320 | 0.85 | ALDH1A1 (0.37) | HSD11B1MAPTSLC29A1PAOXDRD2 | |
| SCHEMBL10930283 | 0.84 | HSD11B1 (0.42) | HSD11B1SLC29A1GBA1KDM4EALDH1A1 | |
| SCHEMBL6057032 | 0.83 | — | — | |
| SCHEMBL4893194 | 0.83 | HSD11B1 (0.47) | HSD11B1TDP1GBA1MEN1KMT2A | |
| SCHEMBL8149011 | 0.83 | HSD11B1 (0.47) | HSD11B1TDP1GBA1MEN1KMT2A | |
| SCHEMBL6945807 | 0.83 | ALDH1A1 (0.38) | HSD11B1MAPTSLC29A1TDP1PAOX | |
| SCHEMBL20231217 | 0.82 | HSD11B1 (0.41) | HSD11B1SLC29A1MEN1KMT2AALDH1A1 | |
| SCHEMBL25135123 | 0.80 | GNAI3 (0.45) | HSD11B1DRD2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820818-B2 | Heteroaryl nitrile derivatives | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20090227596-A1 | HETEROARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| US-7544688-B2 | Hetereoaryl nitrile derivatives | NOVARTIS AG (CH) | 2009-06-09 | — | — | US | disclosed |
| US-7504416-B2 | 4-substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| US-7253184-B2 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2007-08-07 | — | — | US | disclosed |
| EP-1537111-B1 | HETEREOARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-20060142575-A1 | Hetereoaryl nitrile derivatives | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| US-20050101630-A1 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | US | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| EP-1337513-A1 | 4-SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| WO-2002036570-A1 | 4-SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | HSD11B1 4758/4885MAPT 4300/4885SLC29A1 3601/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | HSD11B1 4783/4885MAPT 4124/4885SLC29A1 3195/4885 |
| US-20090227596-A1 | HETEROARYL NITRILE DERIVATIVES | CTSK, CTSS, CTSZ | HSD11B1 1451/4885MAPT 3543/4885SLC29A1 1246/4885 |
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | CCNY, TPD52L2, H1-10 | HSD11B1 4520/4885MAPT 4468/4885SLC29A1 2016/4885 |
| US-20060142575-A1 | Hetereoaryl nitrile derivatives | CTSK, CTSZ, CTSE | HSD11B1 1411/4885MAPT 3738/4885SLC29A1 1738/4885 |
| US-20050101630-A1 | 4-Substituted quinolines as antitumor agents | NQO2, TPD52L2, MLX | HSD11B1 4568/4885MAPT 4637/4885SLC29A1 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.